Workflow
Quantum Biopharma Announces Leading Crusader Against Naked Short Selling and Stock Manipulation, Terry Lynch Elected to Board of Directors
QNTMQuantum Biopharma Ltd.(QNTM) Newsfilter·2025-03-27 11:00

Core Viewpoint - Quantum BioPharma Ltd. has appointed Terry Lynch to its board of directors, replacing Dr. Sanjiv Chopra, who will continue as an advisor to the company [1][3]. Group 1: Appointment Details - Terry Lynch is recognized for founding Save Canadian Mining and has a successful history as an executive in public micro-cap companies [2]. - Lynch is currently the CEO of Power Metallic Mines Inc., which recently secured 50millioninfinancing[2].−Heisalsoaco−founderofCardiolTherapeutics,focusingoncannabidiolforcardiovasculardiseasetreatment[2].Group2:ContributionstotheCompany−CEOZeeshanSaeedhighlightedthreekeycontributionsLynchbrings:extensivefundraisingexperience,biotechinvestmentknowledge,andexpertiseinstockmarketmanipulation[3].−LynchexpressedexcitementaboutjoiningQuantumBioPharma,emphasizingthecompany′spotentialandcommitmenttofairnessincapitalmarkets[3].Group3:StockOptions−ThecompanygrantedLynch50,000stockoptionstoacquireClassBSharesatanexercisepriceofC50 million in financing [2]. - He is also a co-founder of Cardiol Therapeutics, focusing on cannabidiol for cardiovascular disease treatment [2]. Group 2: Contributions to the Company - CEO Zeeshan Saeed highlighted three key contributions Lynch brings: extensive fundraising experience, biotech investment knowledge, and expertise in stock market manipulation [3]. - Lynch expressed excitement about joining Quantum BioPharma, emphasizing the company's potential and commitment to fairness in capital markets [3]. Group 3: Stock Options - The company granted Lynch 50,000 stock options to acquire Class B Shares at an exercise price of C9.90, expiring on March 26, 2027 [3]. Group 4: Company Overview - Quantum BioPharma is focused on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders [4]. - The company is advancing its lead compound, Lucid-MS, aimed at preventing myelin degradation associated with multiple sclerosis [4]. - Quantum BioPharma retains a 25.71% ownership in Celly Nutrition, which includes a royalty agreement on sales from its product unbuzzd™ [4].